Travere Therapeutics (NASDAQ: TVTX) has received a range of analyst ratings in the last three months, showcasing a mix of bullish and bearish perspectives. Over the past month, there have been 2 bullish ratings, 1 somewhat bullish rating, and 3 indifferent ratings. Analysts have set an average 12-month price target of $13.33, with a high estimate of $20.00 and a low estimate of $9.00, indicating a 9.26% increase from the previous average target of $12.20.
Recent analyst actions provide valuable insights:
– Ed Arce from HC Wainwright & Co. has maintained a Buy rating with a price target of $17.00.
– Mohit Bansal at Wells Fargo upgraded the rating to Equal-Weight with a price target of $9.00.
– Laura Chico from Wedbush has kept an Outperform rating with a price target of $13.00.
– Nicole Gabreski at Piper Sandler upgraded the rating to Neutral with a price target of $11.00.
– Alex Thompson from Stifel upgraded the rating to Hold with a price target of $10.00.
These recent analyst actions offer a comprehensive view of how Travere Therapeutics is perceived in the market, reflecting responses to changing market conditions and company performance.
TVTX Stock Shows Promising Signs of Turnaround on March 13, 2024
On March 13, 2024, TVTX stock showed some promising signs of a potential turnaround as it experienced a significant increase in its price. The stock opened at $8.01 and ultimately closed at $8.59, representing a $0.58 increase from the previous close, marking a 7.48% rise in value. Despite this positive price momentum, TVTX is still trading near the bottom of its 52-week range and below its 200-day simple moving average. Investors may want to keep a close eye on TVTX in the coming days to see if this upward trend continues. If the stock is able to sustain its momentum and break through its 200-day moving average, it could signal a more sustained recovery for TVTX. It is important to conduct thorough research and consult with a financial advisor before making any investment decisions. Overall, the performance of TVTX on March 13, 2024, showed some positive signs for the stock, but investors should proceed with caution and closely monitor its movements in the days ahead.
TVTX Stock Performance Analysis: Revenue Decreases, Net Losses Reported
On March 13, 2024, TVTX stock experienced mixed performances based on the financial data provided by CNN Money. The total revenue for the company was reported to be $145.24 million for the past year, showing a significant decrease of 31.5% compared to the previous year. However, the total revenue increased by 21.47% since the last quarter, reaching $45.06 million. In terms of net income, TVTX reported a net loss of -$337.40 million for the past year, indicating a decrease of 21.16% compared to the previous year. In the last quarter, the net loss was reported to be -$88.60 million, showing no change since the previous quarter. Earnings per share (EPS) for TVTX were reported to be -$4.54 for the past year, reflecting a decrease of 4.01% compared to the previous year. In the last quarter, the EPS was reported to be -$1.18, indicating a decrease of 19.72% since the previous quarter. Overall, the financial performance of TVTX stock on March 13, 2024, showed a mix of positive and negative trends. Investors and analysts will likely closely monitor these financial metrics to assess the future performance and potential growth prospects of TVTX stock.
